Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04009460
Other study ID # ES101-1001
Secondary ID CTR20190888
Status Terminated
Phase Phase 1
First received
Last updated
Start date June 28, 2019
Est. completion date April 22, 2022

Study information

Verified date April 2022
Source Elpiscience Biopharma, Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerance and Dose-Limiting Toxicity (DLT) of recombinant humanized PD-L1/4-1BB bispecific antibody (ES101) in patients with advanced solid tumors.


Description:

ES101 (INBRX-105; PDL1x4-1BB antibody) is a recombinant humanized bispecific IgG1 antibody targeting human PD-L1 and 4-1BB. This is an open-label, multicenter, dose-escalation and cohort expansion phase 1 clinical study to evaluate the safety and pharmacokinetic characteristics and preliminary anti-tumor activity of ES101 in patients with advanced malignant solid tumors whose disease has progressed despite standard therapy, or who has no further standard therapy, or who is unsuitable for available standard treatment options.


Recruitment information / eligibility

Status Terminated
Enrollment 22
Est. completion date April 22, 2022
Est. primary completion date April 22, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Males or females aged = 18 years. 2. Subject has pathological or cytological diagnosed advanced malignant solid tumor, whose disease has progressed despite standard therapy, or who has no further standard therapy, or who is unsuitable for available standard treatment options 3. Part A: There is no mandatory requirement for PD-L1 expression status of subject's tumor tissue. Part B:Tumor tissue of subject should be PD-L1 positivity by immunohistochemistry (IHC). 4. Subjects in part A shall have at least one evaluable lesion, and subjects enrolled in part B shall have at least one measurable lesion (RECIST v1.1). Tumor lesions located in previously irradiated (or other local treated) areas will be considered measurable, provided that there has been clear imaging-based progression of the lesions since the time of radiation. 5. Adequate hematologic, coagulation, hepatic and renal function as defined per protocol. 6. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1. 7. Estimated life expectancy, in the judgment of the investigator, of at least 12 weeks. 8. Male and female subjects of childbearing potential and their spouses must be willing to use feasible contraceptive methods considered effective by the investigator, from the time of signing informed consent and for the duration of study participation through 3 months, following the last dose of study drug. Postmenopausal women are considered to have no fertility potential only if menostasis lasts for at least 12 months. 9. Ability to understand and the willingness to sign a written informed consent form Exclusion Criteria: 1. Prior exposure to 4-1BB agonists. 2. Receipt of any anticancer investigational product or any approved drug(s) or biological products (except hormone-replacement therapy, testosterone or oral contraceptives) within 4 weeks prior to the first dose of study drug. Previous exposure to oral fluorouracils or small molecular targeted drugs require a minimum washout period of 2 weeks or 5 half-lives prior to the first dose of study drug (whichever is longer). Previous exposure to mitomycin C or nitrosourea requires a minimum washout period of 6 weeks prior to the first dose of study drug. 3. Known allergies to CHO-produced antibodies, which in the opinion of the Investigator suggests an increased potential for an adverse hypersensitivity to ES101. 4. Primary or metastatic brain or meningeal tumors. 5. Patients with other malignancies previously or currently shall be excluded in Part B. 6. Grade = 3 immune-related adverse events (irAEs) or irAE that lead to discontinuation of prior immunotherapy. Some exceptions as defined per protocol apply. 7. Active autoimmune disease or documented history of autoimmune disease that required systemic steroids or other immunosuppressive medications. Certain exceptions as defined in protocol apply. 8. Treatment with systemic immunosuppressive medications within 4 weeks prior to the first dose of study drug. Certain exceptions as defined in protocol apply. 9. Active interstitial lung disease (ILD) or pneumonitis or a history of ILD or pneumonitis requiring treatment with steroids or immunosuppressive medications.. 10. Subjects who received G-CSF, GM-CSF, Thrombopoietic drugs or EPO within 14 days prior to the first dose of the study drug. 11. Any evidence of hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection. 12. History of hepatitis (non-alcohol steatohepatitis, alcohol or drug-related, autoimmune) or cirrhosis. 13. Clinically significant cardiac condition. 14. History of pulmonary embolism within 12 weeks prior to the first dose of study drug. 15. Major surgery within 4 weeks prior to enrollment on this trial. 16. Systemic anti-infectious drug treatments within 4 weeks prior to the first dose of study drug. 17. Prior organ allograft transplantations or allogeneic peripheral blood stem cell (PBSC) or bone marrow (BM) transplantation. 18. Live viral vaccine therapies within 4 weeks prior to the first dose of study drug. 19. Subject has not recovered from all AEs of previous anticancer therapies to baseline or = Grade 1 per CTCAE v5.0 before teh first dose of study drug. Certain exceptions as defined in protocol apply. 20. Pregnant or nursing females. 21. Any known, documented, or suspected history of substance abuse that would preclude subject from participation, unless clinically justified (i.e., will not interfere with study participation and/or will not compromise trial objectives) per judgment of the Investigator and with approval of the Medical Monitor or Study Director. 22. The subject is inappropriate to participate in this study for other reasons in the judgment of the Investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ES101
ES101 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle.

Locations

Country Name City State
China Shanghai East Hospital Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Elpiscience Biopharma, Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of of ES101 The MTD and/or RP2D of ES101 will be determined. Up to 2-3 years
Primary Frequency of adverse events of ES101 Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0. Up to 2-3 years
Primary Severity of adverse events of ES101 Severity of adverse events will be assessed and assigned by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0. Up to 2-3 years
Secondary Area under the serum concentration time curve (AUC) of ES101 Area under the serum concentration time curve (AUC) of ES101 will be determined. Up to 2-3 years
Secondary Maximum observed serum concentration (Cmax) of ES101 Maximum observed serum concentration (Cmax) of ES101 will be determined. Up to 2-3 years
Secondary Trough observed serum concentration (Ctrough) of ES101 Trough observed serum concentration (Cmax) of ES101 will be determined. Up to 2-3 years
Secondary Time to Cmax (Tmax) of ES101 Time to Cmax (Tmax) of ES101 will be determined. Up to 2-3 years
Secondary Immunogenicity of ES101 Frequency of anti-drug antibodies (ADA) against ES101 will be determined. Up to 2-3 years
Secondary Anti-tumor activity of ES101 Tumor response will be determined by the revised Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1). Up to 2-3 years
See also
  Status Clinical Trial Phase
Completed NCT03826043 - THrombo-Embolic Event in Onco-hematology N/A
Terminated NCT03166631 - A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread Phase 1
Completed NCT01938846 - BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors Phase 1
Recruiting NCT06058312 - Individual Food Preferences for the Mediterranean Diet in Cancer Patients N/A
Completed NCT03308942 - Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants Phase 2
Recruiting NCT06018311 - Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads N/A
Withdrawn NCT05431439 - Omics of Cancer: OncoGenomics
Completed NCT01343043 - A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma Phase 1
Completed NCT01938638 - Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer Phase 1
Recruiting NCT05514444 - Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) Phase 1
Recruiting NCT02292641 - Beyond TME Origins N/A
Terminated NCT00954512 - Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) Phase 1/Phase 2
Recruiting NCT04958239 - A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) Phase 1
Recruiting NCT04627376 - Multimodal Program for Cancer Related Cachexia Prevention N/A
Completed NCT01222728 - Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
Recruiting NCT06004440 - Real World Registry for Use of the Ion Endoluminal System
Active, not recruiting NCT05636696 - COMPANION: A Couple Intervention Targeting Cancer-related Fatigue N/A
Not yet recruiting NCT06035549 - Resilience in East Asian Immigrants for Advance Care Planning Discussions N/A
Recruiting NCT06004466 - Noninvasive Internal Jugular Venous Oximetry
Completed NCT02909348 - Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab